Identification of a novel benzoxazolone derivative as a selective, orally active 18 kDa translocator protein (TSPO) ligand

Journal of Medicinal Chemistry

Volumn 56, Issue 20, 2013, Pages 8191-8195

  Fukaya, Takayuki ^a   Ishiyama, Takeo ^a   Baba, Satoko ^a   Masumoto, Shuji ^a  

^a DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; BENZOXAZOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG IDENTIFICATION; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; MOTOR DYSFUNCTION; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; TRANQUILIZING ACTIVITY;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ANXIETY AGENTS; AREA UNDER CURVE; AVOIDANCE LEARNING; BENZOXAZOLES; CARRIER PROTEINS; CELL LINE, TUMOR; CONFLICT (PSYCHOLOGY); HUMANS; LIGANDS; MALE; MICE; MOLECULAR STRUCTURE; MOTOR ACTIVITY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, GABA-A; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84886552984     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401325r     Document Type: Article

References (29)

1. O'Brien, C. P. Benzodiazepine use, abuse, and dependence J. Clin. Psychiatry 2005, 66, 28-33
2. A receptor subtypes Nat. Rev. Drug Discovery 2011, 10, 685-697
3. Bandelow, B.; Zohar, J.; Hollander, E.; Kasper, S.; Möller, H.-J. World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-complusive and post-traumatic stress disorders-first revision World J. Biol. Psychiatry 2008, 9, 248-312
4. Papadopolous, V.; Baraldi, M.; Guilarte, T. R.; Knudsen, T. B.; Lacapère, J.-J.; Lindemann, P.; Norenberg, M. D.; Nutt, D.; Weizman, A.; Zhang, M.-R.; Gavish, M. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function Trends Pharmacol. Sci. 2006, 27, 402-409
5. 3H]diazepam binding Proc. Natl. Acad. Sci. U.S.A. 1977, 74, 3805-3809
6. Gavish, M.; Bachman, I.; Shoukrun, R.; Katz, Y.; Veenman, L.; Weisinger, G.; Weizman, A. Enigma of the peripheral benzodiazepine receptor Pharmacol. Rev. 1999, 51, 629-650
7. Rupprecht, R.; Papadopoulos, V.; Rammes, G.; Baghai, T. C.; Fan, J.; Akula, N.; Groyer, G.; Adams, D.; Schumacher, M. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders Nat. Rev. Drug Discovery 2010, 9, 971-988
8. Mcenery, M. W.; Snowman, A. M.; Trifiletti, R. R.; Snyder, S. H. Isolation of the mitochondrial benzodiazepine receptor: association with the voltage-dependent anion channel and the adenine nucleotide carrier Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 3170-3174
9. Anholt, R. R. H.; Pedersen, P. L.; De Souza, E. B.; Snyder, S. H. The peripheral-type benzodiazepine receptor: location to the mitochondrial outer membrane J. Biol. Chem. 1986, 261, 576-583
10. Lacapère, J.-J.; Papadopoulos, V. Peripheral-type benzodiazepine receptor: structure and function of a cholesterol-binding protein in steroid and bile acid biosynthesis Steroids 2003, 68, 569-585
11. Papadopoulos, V.; Lecanu, L.; Brown, R. C.; Han, Z.; Yao, Z.-X. Peripheral-type benzodiazepine receptor in neurosteroid biosynthesis, neuropathology and neurological disorders Neuroscience 2006, 138, 749-756
12. Da Pozzo, E.; Costa, B.; Martini, C. Translocator protein (TSPO) and neurosteroids: implications in psychiatric disorders Curr. Mol. Med. 2012, 12, 426-442
13. Stocco, D. M. StAR protein and the regulation of steroid hormone biosynthesis Annu. Rev. Physiol. 2001, 63, 193-213
14. Wolkowitz, O. M.; Reus, V. I.; Keebler, A.; Nelson, N.; Friedland, M.; Brizendine, L.; Roberts, E. Double-blind treatment of major depression with dehydroepiandrosterone Am. J. Psychiatry 1999, 156, 646-649
15. Khisti, R. T.; Chopde, C. T.; Jain, S. P. Antidepressant-like effect of the neurosteroid 3α-hydroxy-5α-pregnan-20-one in mice forced swim test Pharmacol., Biochem. Behav. 2000, 67, 137-143
16. 3H]Ro5-4864 in rat brain and kidney J. Pharmacol. Exp. Ther. 1983, 225, 61-69
17. Le Fur, G.; Perrier, M. L.; Vaucher, N.; Imbault, F.; Flamier, A.; Benavides, J.; Uzan, A.; Renault, C.; Dubroeucq, M. C.; Guérémy, C. Peripheral benzodiazepine binding sites: effect of PK11195, 1-(2-chlorophenyl)- N -methyl- N -(1-methylpropyl)-3-isoquinolinecarboxamide I. In vitro studies Life Sci. 1983, 32, 1839-1847
18. Romeo, E.; Auta, J.; Kozikowski, A. P.; Ma, D.; Papadopoulos, V.; Puia, G.; Costa, E.; Guidotti, A. 2-AryI-3-Indoleacetamides (FGIN-1): a new class of potent and specific ligands for the mitochondrial DBI receptor (MDR) J. Pharmacol. Exp. Ther. 1992, 262, 971-978
19. Kita, A.; Kohayakawa, H.; Kinoshita, T.; Ochi, Y.; Nakamichi, K.; Kurumiya, S.; Furukawa, K.; Oka, M. Antianxiety and antidepressant-like effects of AC-5216, a novel mitochondrial benzodiazepine receptor ligand Br. J. Pharmacol. 2004, 142, 1059-1072
20. Rupprecht, R.; Rammes, G.; Eser, D.; Baghai, T. C.; Schüle, C.; Nothdurfter, C.; Troxler, T.; Gentsch, C.; Kalkman, H. O.; Chaperon, F.; Uzunov, V.; McAllister, K. H.; Bertaina-Anglade, V.; La Rochelle, C. D.; Tuerck, D.; Floesser, A.; Kiese, B.; Schumacher, M.; Landgraf, R.; Holsboer, F.; Kucher, K. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects Science 2009, 325, 490-493
21. Da Settimo, F.; Simorini, F.; Taliani, S.; La Motta, C.; Marini, A. M.; Salerno, S.; Bellandi, M.; Novellino, E.; Greco, G.; Cosimelli, B.; Da Pozzo, E.; Costa, B.; Simola, N.; Morelli, M.; Martini, C. Anxiolytic-like effects of N, N -dialkyl-2-phenylindol-3-ylglyoxyamides by modulation of translocator protein promoting neurosteroid biosynthesis J. Med. Chem. 2008, 51, 5798-5806
22. Cappelli, A.; Bini, G.; Valenti, S.; Giuliani, G.; Paolino, M.; Anzini, M.; Vomero, S.; Giorgi, G.; Giordani, A.; Stasi, L. P.; Makovec, F.; Ghelardini, C.; Di Cesare Mannelli, L.; Concas, A.; Porcu, P.; Biggio, G. Synthesis and structure-activity relationship studies in translocator protein ligands based on a pyrazolo[3,4- b ]quinoline scaffold J. Med. Chem. 2011, 54, 7165-7175
23. Fukaya, T.; Kodo, T.; Ishiyama, T.; Kakuyama, H.; Nishikawa, H.; Baba, S.; Masumoto, S. Design, synthesis and structure-activity relationships of novel benzoxazolone derivatives as 18 kDa translocator protein (TSPO) ligands Bioorg. Med. Chem. 2012, 20, 5568-5582
24. Campiani, G.; Nacci, V.; Fiorini, I.; De Filippis, M. P.; Garofalo, A.; Ciani, S. M.; Greco, G.; Novellino, E.; Williams, D. C.; Zisterer, D. M.; Woods, M. J.; Mihai, C.; Manzoni, C.; Mennini, T. Synthesis, biological activity, and SARs of pyrrolobenzoxazepine derivatives, a new class of specific "peripheral-type" benzodiazepine receptor ligands J. Med. Chem. 1996, 39, 3435-3450
25. Anzini, M.; Cappelli, A.; Vomero, S.; Giorgi, G.; Langer, T.; Bruni, G.; Romeo, M. R.; Basile, A. S. Molecular basis of peripheral vs central benzodiazepine receptor selectivity in a new class of peripheral benzodiazepine receptor ligands related to alpidem J. Med. Chem. 1996, 39, 4275-4284
26. Vogel, J. R.; Beer, B.; Clody, D. E. A simple and reliable conflict procedure for testing anti-anxiety agents Psycopharmacologia 1971, 21, 1-7
27. Anger, T.; Madge, D. J.; Mulla, M.; Riddall, D. Medicinal chemistry of neuronal voltage-gated sodium channel blockers J. Med. Chem. 2001, 44, 115-137
28. v1.6) in cerebellar purkinje neurons and granule cells J. Neurophysiol. 2006, 96, 785-793
29. v1.1 mutant mice: implications for ataxia in severe myoclonic epilepsy in infancy J. Neurosci. 2007, 27, 11065-11074